CG Oncology, Inc. (CGON) Stock Forecast & Price Target

Compare

244 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CGON Analyst Ratings

Strong Buy

13 Buy

0 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Oncology, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CGON Stock 12 Month Forecast

Average Price Target

$70.09

▲(69.42% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for CG Oncology, Inc. in the last 3 months. The average price target is $70.09 with a high forecast of $90.00 and a low forecast of $55.00. The average price target represents a 69.42% change from the last price of $41.37.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","56":"$56","91":"$91","38.5":"$38.5","73.5":"$73.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70.09,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$70.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$55.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,38.5,56,73.5,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.27,46.86461538461539,50.45923076923077,54.05384615384616,57.64846153846154,61.24307692307693,64.83769230769231,68.43230769230769,72.02692307692308,75.62153846153846,79.21615384615384,82.81076923076924,86.40538461538462,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.27,45.33307692307692,47.39615384615385,49.45923076923077,51.52230769230769,53.58538461538462,55.64846153846154,57.71153846153847,59.77461538461539,61.83769230769231,63.900769230769235,65.96384615384616,68.02692307692308,{"y":70.09,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.27,44.1723076923077,45.074615384615385,45.97692307692308,46.87923076923077,47.78153846153846,48.683846153846154,49.58615384615385,50.488461538461536,51.39076923076923,52.293076923076924,53.19538461538461,54.097692307692306,{"y":55,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":35.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.77,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.68,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.07,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.86,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$90.00

Average Price Target$70.09

Lowest Price Target$55.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Truist Financial

Not Ranked

Truist Financial

―

Buy

―

Reiterated

11/28/25

Leonid Timashev

RBC Capital

$61

Buy

47.45%

Upside

Reiterated

11/26/25

RBC Capital Reaffirms Their Buy Rating on CG Oncology, Inc. (CGON)

Sam Slutsky

LifeSci Capital

$90

Buy

117.55%

Upside

Reiterated

11/26/25

Promising Developments in CG Oncology's NMIBC Treatment Drive Buy Recommendation

Kelsey Goodwin

Piper Sandler

$55

Buy

32.95%

Upside

Reiterated

11/26/25

Piper Sandler Remains a Buy on CG Oncology, Inc. (CGON)

Unknown Analyst

Truist Financial

Not Ranked

Truist Financial

$62

Buy

49.87%

Upside

Initiated

11/24/25

CG Oncology, Inc. (CGON) Has a New Rating from Truist Financial

Andres Y. Maldonado

H.C. Wainwright

$75

Buy

81.29%

Upside

Reiterated

11/17/25

Buy Rating Affirmed for CG Oncology: Promising Advancements and Market Potential of CretostimogeneValuation and risks to achievement of price target. Our 12-month price target of $75 is based on an equally weighted composite of (a) 88.01/share, as a 20x multiple of taxed and diluted FY34 GAAP EPS of $12.20 discounted back to and (b) an NPV of $62.2/ share (discount rate 12.0%, growth rate 3.0%). The assumptions are in line with the expected P/ E multiple and discount rate of a late development-stage biopharmaceutical company. Risks to achieving our price target include the following: 1) Clinical risk.

Bradley Canino

Guggenheim

$90

Buy

117.55%

Upside

Reiterated

11/17/25

Guggenheim Reaffirms Their Buy Rating on CG Oncology, Inc. (CGON)

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

11/14/25

CG Oncology, Inc.: Promising Future with Creto's Accelerated Approval Path and Market DifferentiationWe have high confidence in creto's approval, especially following the fourth approval (TAR-200) in this setting with a similarly designed pivotal study. At SUO on Dec 3rd, CG will also report BOND- 003 Cohort P (papillary) and CORE-008 Cohort A (BCG-naive) data.

Sean Laaman

Morgan Stanley

$79

Buy

90.96%

Upside

Reiterated

11/14/25

Strategic Advancements and Risk Mitigation Drive Buy Rating for CG Oncology, Inc.

Alec Stranahan

Bank of America Securities

$62→$60

Buy

45.03%

Upside

Reiterated

11/14/25

CG Oncology price target lowered to $60 from $62 at BofACG Oncology price target lowered to $60 from $62 at BofA

Brian Cheng

J.P. Morgan

$47→$55

Buy

32.95%

Upside

Reiterated

11/14/25

J.P. Morgan Sticks to Its Buy Rating for CG Oncology, Inc. (CGON)

Soumit Roy

JonesTrading

$75

Buy

81.29%

Upside

Reiterated

11/14/25

CG Oncology's Promising Advances in NMIBC Treatment Drive Buy Rating with $75 Target

Corinne Johnson

Goldman Sachs

$40→$56

Buy

35.36%

Upside

Reiterated

09/22/25

Goldman Sachs Remains a Buy on CG Oncology, Inc. (CGON)

Joshua Schimmer

Cantor Fitzgerald

$75

Buy

81.29%

Upside

Reiterated

09/07/25

Cantor Fitzgerald Keeps Their Buy Rating on CG Oncology, Inc. (CGON)

David Dai

UBS

$60

Buy

45.03%

Upside

Reiterated

08/18/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Truist Financial

Not Ranked

Truist Financial

―

Buy

―

Reiterated

11/28/25

Leonid Timashev

RBC Capital

$61

Buy

47.45%

Upside

Reiterated

11/26/25

RBC Capital Reaffirms Their Buy Rating on CG Oncology, Inc. (CGON)

Sam Slutsky

LifeSci Capital

$90

Buy

117.55%

Upside

Reiterated

11/26/25

Promising Developments in CG Oncology's NMIBC Treatment Drive Buy Recommendation

Kelsey Goodwin

Piper Sandler

$55

Buy

32.95%

Upside

Reiterated

11/26/25

Piper Sandler Remains a Buy on CG Oncology, Inc. (CGON)

Unknown Analyst

Truist Financial

Not Ranked

Truist Financial

$62

Buy

49.87%

Upside

Initiated

11/24/25

CG Oncology, Inc. (CGON) Has a New Rating from Truist Financial

Andres Y. Maldonado

H.C. Wainwright

$75

Buy

81.29%

Upside

Reiterated

11/17/25

Bradley Canino

Guggenheim

$90

Buy

117.55%

Upside

Reiterated

11/17/25

Guggenheim Reaffirms Their Buy Rating on CG Oncology, Inc. (CGON)

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

11/14/25

Sean Laaman

Morgan Stanley

$79

Buy

90.96%

Upside

Reiterated

11/14/25

Strategic Advancements and Risk Mitigation Drive Buy Rating for CG Oncology, Inc.

Alec Stranahan

Bank of America Securities

$62→$60

Buy

45.03%

Upside

Reiterated

11/14/25

CG Oncology price target lowered to $60 from $62 at BofACG Oncology price target lowered to $60 from $62 at BofA

Brian Cheng

J.P. Morgan

$47→$55

Buy

32.95%

Upside

Reiterated

11/14/25

J.P. Morgan Sticks to Its Buy Rating for CG Oncology, Inc. (CGON)

Soumit Roy

JonesTrading

$75

Buy

81.29%

Upside

Reiterated

11/14/25

CG Oncology's Promising Advances in NMIBC Treatment Drive Buy Rating with $75 Target

Corinne Johnson

Goldman Sachs

$40→$56

Buy

35.36%

Upside

Reiterated

09/22/25

Goldman Sachs Remains a Buy on CG Oncology, Inc. (CGON)

Joshua Schimmer

Cantor Fitzgerald

$75

Buy

81.29%

Upside

Reiterated

09/07/25

Cantor Fitzgerald Keeps Their Buy Rating on CG Oncology, Inc. (CGON)

David Dai

UBS

$60

Buy

45.03%

Upside

Reiterated

08/18/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CG Oncology, Inc.

1 Month

xxx

Success Rate

4/6 ratings generated profit

Average Return

+10.05%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +10.05% per trade.

3 Months

xxx

Success Rate

4/6 ratings generated profit

Average Return

+19.00%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +19.00% per trade.

1 Year

Tyler Van BurenTD Cowen

Success Rate

8/8 ratings generated profit

Average Return

+46.79%

reiterated a buy rating 21 days ago

Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +46.79% per trade.

2 Years

xxx

Success Rate

8/8 ratings generated profit

Average Return

+46.79%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +46.79% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CGON Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CGON has received 34 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. CGON average Analyst price target in the past 3 months is 70.09.

Each month's total comprises the sum of three months' worth of ratings.

CGON Financial Forecast

CGON Earnings Forecast

Next quarter’s earnings estimate for CGON is -$0.61 with a range of -$0.70 to -$0.50. The previous quarter’s EPS was -$0.57. CGON beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CGON has Performed in-line its overall industry.

CGON Sales Forecast

Next quarter’s sales forecast for CGON is $530.00K with a range of $0.00 to $5.00M. The previous quarter’s sales results were $1.67M. CGON beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CGON has Performed in-line its overall industry.

CGON Stock Forecast FAQ

What is CGON’s average 12-month price target, according to analysts?

Based on analyst ratings, CG Oncology, Inc.’s 12-month average price target is 70.09.

What is CGON’s upside potential, based on the analysts’ average price target?

CG Oncology, Inc. has 69.42% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CGON a Buy, Sell or Hold?

CG Oncology, Inc. has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.

What is CG Oncology, Inc.’s price target?

The average price target for CG Oncology, Inc. is 70.09. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $90.00 ,the lowest forecast is $55.00. The average price target represents 69.42% Increase from the current price of $41.37.

What do analysts say about CG Oncology, Inc.?

CG Oncology, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of CGON?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

CG Oncology, Inc. (CGON) Stock Forecast & Price Target

CGON Analyst Ratings

CGON Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering CG Oncology, Inc.

CGON Analyst Recommendation Trends

CGON Financial Forecast

CGON Earnings Forecast

CGON Sales Forecast

CGON Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts